poisar

Stocks · News reference

Viking Therapeutics Reports Renewed Takeover Interest

Fiscal.ai

Viking Therapeutics shares rose following reports of renewed takeover interest in the clinical-stage biopharmaceutical company.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolLee Samaha

    Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

    Viking Therapeutics is conducting phase 3 trials for its obesity drug VK2735 in both injectable and oral forms. The oral formulation could expand the addressable market through a dual-dosing strategy. With conservative assumptions of 50% phase 3 success rate and 10% market share of tirzepatide's peak sales, Viking's stock could reach $110 per share by 2028, making a $10,000 investment worth up to $47,800.

  2. The Motley FoolProsper Junior Bakiny

    Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

    Eli Lilly raised its 2026 sales forecast to $91-92 billion, driven by strong Zepbound weight-loss drug sales. While smaller competitor Viking Therapeutics shows promise with its VK2735 candidate demonstrating encouraging clinical trial results, Eli Lilly's diversified pipeline and market leadership position it well to withstand competition. Viking offers high upside potential but carries significant clinical and regulatory risks.

  3. Globenewswire IncDelveinsight

    GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

    DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

  4. The Motley FoolAdria Cimino

    Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

    Viking Therapeutics is trading 23% below its recent $35 secondary offering price after raising $575 million for phase 3 development of its weight loss drug VK2735. Despite the post-offering stock decline due to dilution concerns, the article argues this presents a buying opportunity for patient investors, as Viking is advancing dual GLP-1/GIP receptor agonist candidates in injectable and oral formats while the weight loss drug market is projected to reach nearly $100 billion by decade's end.